Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical has disclosed that its subsidiary Jisimei (Wuhan) Pharmaceutical has had a drug registration application for a Cisplatin Injection accepted by China’s National Medical Products Administration. The chemotherapy product, independently developed by the Fosun group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer, underscoring the company’s continued push in oncology therapeutics.
The group has invested about RMB4.69 million in the drug’s R&D so far, positioning it to compete in a domestic cisplatin injection market that IQVIA data estimates generated roughly RMB165 million in 2024. Acceptance of the application marks a regulatory milestone that could expand Fosun Pharma’s oncology portfolio and revenue base in China’s hospital-driven cancer drug market if the product ultimately wins approval and gains market traction.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based healthcare group engaged in the research, development, manufacturing and distribution of pharmaceutical products. Through its subsidiaries, the company focuses on prescription drugs across oncology and other therapeutic areas, targeting hospital and broader medical markets in mainland China and overseas.
Average Trading Volume: 3,805,318
Technical Sentiment Signal: Buy
Current Market Cap: HK$76.87B
See more data about 2196 stock on TipRanks’ Stock Analysis page.